[go: up one dir, main page]

PE20080183A1 - TRA COMBINATION THERAPIES - Google Patents

TRA COMBINATION THERAPIES

Info

Publication number
PE20080183A1
PE20080183A1 PE2007000416A PE2007000416A PE20080183A1 PE 20080183 A1 PE20080183 A1 PE 20080183A1 PE 2007000416 A PE2007000416 A PE 2007000416A PE 2007000416 A PE2007000416 A PE 2007000416A PE 20080183 A1 PE20080183 A1 PE 20080183A1
Authority
PE
Peru
Prior art keywords
refers
tra
receptor antagonist
combination therapies
receptor
Prior art date
Application number
PE2007000416A
Other languages
Spanish (es)
Inventor
Enrico P Veltri
William J Greenlee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080183A1 publication Critical patent/PE20080183A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA RECEPTOR DE TROMBINA Y UN AGENTE CARDIOVASCULAR SELECCIONADO DE BLOQUEDORES DE CANALES DE CALCIO TAL COMO AMLODIPINA, DILTIAZEM, VERAPAMIL, ENTRE OTROS, ESTATINAS TALES COMO FLUVASTATINA, LOVASTATINA, PRAVASTATINA, ENTRE OTROS, HEPARINAS DE BAJO PESO MOLECULAR SELECCIONADO DE DALTEPARINA, ARDEPARINA, ENOXAPARINA, ENTRE OTROS, ANTIARRITMICOS SELECCIONADOS DE DOFETILIDA, ATENOLOL, PROPANOLOL, ENTRE OTROS, BLOQUEDORES ADRENERGICOS, IECA, BLOQUEADOR DEL RECEPTOR ANGIOTENSINA II, ANTAGONISTA DE ENDOTELINA, ENTRE OTROS. UN ANTAGONISTA RECEPTOR DE TROMBINA ES A, B, C, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE SINDROMES CORONARIOS Y PREVENCION SECUNDARIA EN PACIENTES SUCEPTIBLES A EVENTOS CARDIOVASCULARESREFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES A TROMBIN RECEPTOR ANTAGONIST AND A CARDIOVASCULAR AGENT SELECTED FROM CALCIUM CHANNEL BLOCKERS SUCH AS AMLODIPINE, DILTIAZEM, VERAPAMIL, BETWEEN OTHERS, LOVASTRAIN OTHERS, STATUVASTINAS TALES SELECTED MOLECULAR WEIGHT OF DALTEPARIN, ARDEPARIN, ENOXAPARIN, AMONG OTHERS, SELECTED ANTIARRHYTHMICS OF DOFETILIDE, ATENOLOL, PROPANOLOL, AMONG OTHERS, ADRENERGIC BLOCKERS, ANGOTHETIC, RECEPTOR II BLOCKER. A THROMBINE RECEPTOR ANTAGONIST IS A, B, C, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF CORONARY SYNDROMES AND SECONDARY PREVENTION IN PATIENTS SUBSEQUENT TO CARDIOVASCULAR EVENTS

PE2007000416A 2006-04-06 2007-04-04 TRA COMBINATION THERAPIES PE20080183A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79046906P 2006-04-06 2006-04-06
US80861106P 2006-05-26 2006-05-26
US80978506P 2006-05-31 2006-05-31
US83947406P 2006-08-23 2006-08-23
US83948406P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
PE20080183A1 true PE20080183A1 (en) 2008-03-10

Family

ID=38458156

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000416A PE20080183A1 (en) 2006-04-06 2007-04-04 TRA COMBINATION THERAPIES

Country Status (11)

Country Link
EP (1) EP2001471A1 (en)
JP (1) JP2009532487A (en)
AR (1) AR060354A1 (en)
AU (1) AU2007235353A1 (en)
BR (1) BRPI0710840A2 (en)
CA (1) CA2648613A1 (en)
MX (1) MX2008012933A (en)
NO (1) NO20084677L (en)
PE (1) PE20080183A1 (en)
TW (1) TW200812619A (en)
WO (1) WO2007117621A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
CA2708418C (en) * 2007-12-11 2013-11-12 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment and/or prophylaxis of heart failure
CA2711612A1 (en) * 2008-01-11 2009-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
JP2012529431A (en) * 2009-06-08 2012-11-22 メルク・シャープ・アンド・ドーム・コーポレーション Fixed dose tablets of thrombin receptor antagonist and clopidogrel
US20130183392A1 (en) * 2011-07-15 2013-07-18 Steven Moore Insect repellant and system
KR20140028971A (en) * 2012-08-31 2014-03-10 한미약품 주식회사 Bilayered tablet composite formulation of atorvastatin, irbesartan and magnesium carbonate
CN105125504A (en) * 2015-09-17 2015-12-09 青岛华之草医药科技有限公司 Composition granules of blood lipid-lowering drug pitavastatin calcium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
ATE494284T1 (en) * 2002-04-16 2011-01-15 Schering Corp TRICYCLIC THROMBIN RECEPTOR ANTAGONIST
EP1751144B1 (en) * 2004-05-28 2008-08-27 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
EP2075250B1 (en) * 2004-10-08 2015-03-04 Merck Sharp & Dohme Corp. Thrombin receptor antagonists
EP1863778B1 (en) * 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
CN101384259A (en) * 2005-12-22 2009-03-11 先灵公司 Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
KR20080083672A (en) * 2005-12-22 2008-09-18 쉐링 코포레이션 Oxazoloisoquinoline derivatives as thrombin receptor antagonists

Also Published As

Publication number Publication date
NO20084677L (en) 2008-11-05
CA2648613A1 (en) 2007-10-18
AU2007235353A1 (en) 2007-10-18
WO2007117621A1 (en) 2007-10-18
AR060354A1 (en) 2008-06-11
JP2009532487A (en) 2009-09-10
BRPI0710840A2 (en) 2011-08-23
TW200812619A (en) 2008-03-16
MX2008012933A (en) 2008-10-15
EP2001471A1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
PE20080183A1 (en) TRA COMBINATION THERAPIES
GT201400102A (en) 4-PHENYL-PYRIDINES REPLACED FOR THE TREATMENT OF DISEASES RELATED TO THE RECEIVER OF NK1
CL2013000713A1 (en) Pirazin-2-carbonyl-imino-1,3,8-triaza-spiro- [4.5] -decan-substituted compounds, epithelial sodium channel blockers (enac); pharmaceutical composition that includes them; prevention or treatment method; and its use to treat a disease or condition mediated by blockade of the epithelial sodium channel.
CR20110450A (en) SOLID PHARMACEUTICAL COMPOSITION INCLUDING AMLODIPINA AND LOSARTAN
ECSP12012270A (en) PIRAZOL COMPOUNDS AS INHIBITORS OF THE SIGMA RECEIVER
CL2011003147A1 (en) Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer.
DOP2011000120A (en) ISONICOTINAMIDE OREXINE RECEIVER ANTAGONISTS
CL2012003211A1 (en) Compounds derived from piperidinyl substituted lactams, modulators of gpr119; process to prepare the compounds; pharmaceutical composition comprising the compounds; and use of the compounds in the preparation of medicaments for the treatment or prevention of type 2 diabetes, obesity and related conditions
UY32819A (en) PHARMACEUTICAL COMPOSITIONS OF OPTALMIC USE OF ANTAGONISTS OF DP2 RECEIVER
UY37981A (en) NEW BRADIQUININE B2 RECEIVER ANTAGONISTS
ZA201007170B (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
CL2013003527A1 (en) Heterocyclic antagonist compounds of muscarinic receptors and agonists of the beta2 adrenergic receptor; its pharmaceutical composition; its combination; a device and its use in the prevention and / or treatment of broncho-obstructive or inflammatory diseases such as asthma and epoc.
CL2012002716A1 (en) Use of a dgat1 inhibitor compound because it is useful in the prevention, delay of progress or treatment of a disease or condition selected from chylomicronemia, familial chylomicronemia syndrome and type v hyperlipoproteinemia; a compound derived from substituted heteroaryl; pharmaceutical composition
EA201401193A1 (en) TRIAILARY COMPOUNDS AND COMPOSITIONS CONTAINING THEM
AR080295A1 (en) COMPOSITIONS FOR ORAL CARE AND TREATMENT METHODS
PH12012500754A1 (en) Pharmaceutical composition comprising oligopeptides
ECSP15007358A (en) PIRROL CARBOXAMIDES SUBSTITUTED FLUOROMETHYL
GT201300241A (en) ANTIHIPERTENSIVE PHARMACEUTICAL COMPOSITION
CL2008000430A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED CONDENSED HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS, USEFUL FOR THE TREATMENT OF ONE OR MORE CONDITIONS ASSOCIATED WITH A2C ADRENERGIC RECEIVERS, SUCH AS CONGESTION ASSOCIATED WITH
MX2014007042A (en) Compositions of buprenorphine and mu-opioid receptor antagonists.
CR20110302A (en) ESPIRO AZEPAN OXAZOLIDINONAS AS BLOCKERS OF THE POTASSIUM CHANNEL Kv1.3
UY33509A (en) METHODS AND COMPOSITIONS FOR ALLERGY TREATMENT
UY38707A (en) NEW CYCLIC ANTAGONISTS OF BRADIQUININ B2 RECEPTOR
EA201170913A1 (en) PHARMACEUTICAL COMPOSITIONS OF OLMESARTAN
EA201290851A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF THE SYMPTOMS OF HORMONAL CHANGES

Legal Events

Date Code Title Description
FC Refusal